Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500438 | 0.91 | TNK2 (0.44) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL11892016 | 0.89 | ACHE (0.39) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL21780925 | 0.88 | MEN1 (0.47) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL813805 | 0.86 | NPC1 (0.46) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL23677866 | 0.83 | TNK2 (0.41) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL7231933 | 0.83 | NPY1R (0.54) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL4382295 | 0.83 | MEN1 (0.45) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL1457107 | 0.83 | NPY1R (0.43) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL5708685 | 0.82 | MEN1 (0.44) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL5535757 | 0.82 | TNK2 (0.40) | TNK2HSD11B1MEN1KMT2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2022210901-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | 日産化学株式会社 | 2022-10-06 | — | — | WO | disclosed |
| EP-3892618-A1 | 4-PYRIDINYL FORMAMIDE COMPOUND OR DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | Qingdao KingAgroot Chemical Compound Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-10376479-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| US-10252967-B2 | Bridged bi-aromatic ligands and transition metal compounds prepared therefrom | UNIVATION TECHNOLOGIES, LLC (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3286202-B1 | BRIDGED BI-AROMATIC LIGANDS AND TRANSITION METAL COMPOUNDS PREPARED THEREFROM | UNIVATION TECH LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20180086685-A1 | BRIDGED BI-AROMATIC LIGANDS AND TRANSITION METAL COMPOUNDS PREPARED THEREFROM | UNIVATION TECHNOLOGIES, LLC (US) | 2018-03-29 | — | — | US | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| WO-2008070463-A9 | ENDOXIFEN METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008070463-A2 | ENDOXIFEN METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
| CN-100343232-C | Bisimide compound, acid generator and resist composition using the same, and pattern forming method using the composition | WAKO PURE CHEM IND LTD (JP) | 2007-10-17 | — | — | CN | disclosed |
| CN-1592738-A | Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition | WAKO PURE CHEM IND LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| US-6541490-B1 | Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt | EUKARION, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1119573-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6177419-B1 | ANTIOXIDANT CHELATE COMPOUNDS FOR PREVENTING OXYGEN FREE RADICAL-ASSOCIATED DISEASES IN MAMMALS; NEUROPROTECTANTS, SUPEROXIDE DISMUTASE (SOD), CATALASE (CAT) AND/OR PEROXIDASE (POD) MIMETICS | EUKARION, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000009512-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | TNK2 2672/4885HSD11B1 3709/4885MEN1 763/4885 |
| US-10376479-B2 | Endoxifen compositions and methods | CYP46A1, PLA2G2F, VDR | TNK2 1702/4885HSD11B1 625/4885MEN1 1461/4885 |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | NLN, BDNF, LITAF | TNK2 2698/4885HSD11B1 1963/4885MEN1 3386/4885 |
| US-20180086685-A1 | BRIDGED BI-AROMATIC LIGANDS AND TRANSITION METAL COMPOUNDS PREPARED THEREFROM | WEE2, WEE1, AHR | TNK2 2218/4885HSD11B1 4517/4885MEN1 4617/4885 |
| US-10252967-B2 | Bridged bi-aromatic ligands and transition metal compounds prepared therefrom | WEE2, WEE1, AHR | TNK2 2218/4885HSD11B1 4517/4885MEN1 4617/4885 |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | TNK2 1246/4885HSD11B1 767/4885MEN1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.